Marktanalyse - Neurofibromatoses - Pipeline Review, H2 2016

Global Markets Direct
12.2016
71 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Neurofibromatoses - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses — Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape.

Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and café au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses (Genetic Disorders)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neurofibromatoses (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Neurofibromatoses Overview 7

Therapeutics Development 8

Pipeline Products for Neurofibromatoses - Overview 8

Pipeline Products for Neurofibromatoses - Comparative Analysis 9

Neurofibromatoses - Therapeutics under Development by Companies 10

Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes 11

Neurofibromatoses - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Neurofibromatoses - Products under Development by Companies 14

Neurofibromatoses - Products under Investigation by Universities/Institutes 15

Neurofibromatoses - Companies Involved in Therapeutics Development 16

Alexion Pharmaceuticals Inc 16

Arno Therapeutics Inc 17

AstraZeneca Plc 18

Betta Pharmaceuticals Co Ltd 19

Celldex Therapeutics Inc 20

Lixte Biotechnology Holdings Inc 21

Novartis AG 22

Plex Pharmaceuticals Inc 23

Neurofibromatoses - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AR-42 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

asfotase alfa - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CDX-0158 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

everolimus - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

FRAX-597 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

icotinib hydrochloride - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

LB-201 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

LB-205 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

OS-342 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

selumetinib sulfate - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecules for Neurofibromatoses Type I - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

VAL-0524 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Neurofibromatoses - Dormant Projects 67

Neurofibromatoses - Discontinued Products 68

Neurofibromatoses - Product Development Milestones 69

Featured News & Press Releases 69

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71





List of Tables

Number of Products under Development for Neurofibromatoses, H2 2016 8

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Neurofibromatoses - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 16

Neurofibromatoses - Pipeline by Arno Therapeutics Inc, H2 2016 17

Neurofibromatoses - Pipeline by AstraZeneca Plc, H2 2016 18

Neurofibromatoses - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 19

Neurofibromatoses - Pipeline by Celldex Therapeutics Inc, H2 2016 20

Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 21

Neurofibromatoses - Pipeline by Novartis AG, H2 2016 22

Neurofibromatoses - Pipeline by Plex Pharmaceuticals Inc, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Neurofibromatoses - Dormant Projects, H2 2016 67

Neurofibromatoses - Discontinued Products, H2 2016 68





List of Figures

Number of Products under Development for Neurofibromatoses, H2 2016 8

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Top 10 Targets, H2 2016 25

Number of Products by Stage and Top 10 Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus